Northwest Biotherapeutics (NWBO) Income towards Parent Company (2010 - 2026)

Northwest Biotherapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$13.2 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 29.96% year-over-year to -$13.2 million; the TTM figure through Mar 2026 stood at -$71.1 million (down 4.03% YoY), while the FY2025 annual figure was -$60.7 million, up 27.55% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$13.2 million, up from -$16.1 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$11.2 million in Q4 2023, with the low at -$130.2 million in Q3 2022.
• The 5-year median for Income towards Parent Company is -$16.9 million (2024), against an average of -$23.4 million.
• The sharpest annual moves came in 2022 and 2023: Income towards Parent Company plunged 1017.61% in 2022, then surged 88.08% in 2023.
• Northwest Biotherapeutics' Income towards Parent Company stood at -$19.0 million in 2022, then jumped by 41.19% to -$11.2 million in 2023, then slipped by 19.23% to -$13.4 million in 2024, then decreased by 20.79% to -$16.1 million in 2025, then grew by 17.86% to -$13.2 million in 2026.
• Business Quant data shows NWBO's Income towards Parent Company at -$13.2 million in Q1 2026, -$16.1 million in Q4 2025, and -$16.9 million in Q3 2025.